scholarly journals Self‐Weighing Increases Weight Loss in Free‐Living Adults: A Double‐Blind Randomized Field Trial among 200,000 Health App Users

2015 ◽  
Vol 29 (S1) ◽  
Author(s):  
Sarah Novello ◽  
Sean Cash ◽  
Susan Roberts ◽  
William Masters
Keyword(s):  
Weight Loss ◽  
Field Trial ◽  
Free Living ◽  
Double Blind ◽  
Randomized Field Trial

scholarly journals Vitamin E supplementation during the dry period in dairy cattle. Part I: Adverse effect on incidence of mastitis postpartum in a double-blind randomized field trial

2010 ◽  
Vol 93 (12) ◽  
pp. 5684-5695 ◽  
Author(s):  
R.J. Bouwstra ◽  
M. Nielen ◽  
J.A. Stegeman ◽  
P. Dobbelaar ◽  
J.R. Newbold ◽  
...  
Keyword(s):  
Adverse Effect ◽  
Vitamin E ◽  
Dairy Cattle ◽  
Field Trial ◽  
Dry Period ◽  
Double Blind ◽  
Randomized Field Trial ◽  
Vitamin E Supplementation

scholarly journals Response to Letter to the Editor: “Effectiveness of Prenatal Vitamin D Deficiency Screening and Treatment Program: A Stratified Randomized Field Trial”

2018 ◽  
Vol 104 (2) ◽  
pp. 339-340
Author(s):  
Fahimeh Ramezani Tehrani ◽  
Sonia Minooee ◽  
Maryam Rostami ◽  
Razieh Bidhendi Yarandi ◽  
Farhad Hosseinpanah
Keyword(s):  
Vitamin D ◽  
Vitamin D Deficiency ◽  
Treatment Program ◽  
Field Trial ◽  
Letter To The Editor ◽  
Randomized Field Trial ◽  
Deficiency Screening

scholarly journals Effect of liraglutide on body weight and pain in patients with overweight and knee osteoarthritis: protocol for a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial

BMJ Open ◽  
2019 ◽  
Vol 9 (5) ◽  
pp. e024065 ◽  
Author(s):  
Henrik Gudbergsen ◽  
Marius Henriksen ◽  
Eva Ejlersen Wæhrens ◽  
Anders Overgaard ◽  
Henning Bliddal ◽  
...  
Keyword(s):  
Weight Loss ◽  
Body Weight ◽  
Knee Osteoarthritis ◽  
Controlled Trial ◽  
Single Centre ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Knee Oa ◽  
Parallel Group ◽  
Pain Subscale

IntroductionWith an increasing prevalence of citizens of older age and with overweight, the health issues related to knee osteoarthritis (OA) will intensify. Weight loss is considered a primary management strategy in patients with concomitant overweight and knee OA. However, there are no widely available and feasible methods to sustain weight loss in patients with overweight and knee OA. The present protocol describes a randomised controlled trial evaluating the efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide in a 3 mg/day dosing in patients with overweight and knee OA.Methods and analysis150 volunteer adult patients with overweight or obesity and knee OA will participate in a randomised, double-blind, placebo-controlled, parallel-group and single-centre trial. The participants will partake in a run-in diet intervention phase (week −8 to 0) including a low calorie diet and dietetic counselling. At week 0, patients will be randomised to either liraglutide 3 mg/day or liraglutide placebo 3 mg/day for 52 weeks as an add-on to dietetic guidance on re-introducing regular foods and a focus on continued motivation to engage in a healthy lifestyle. The co-primary outcomes are changes in body weight and the Knee Injury and Osteoarthritis Outcome Score pain subscale from week 0 to week 52.Ethics and disseminationThe trial has been approved by the regional ethics committee in the Capital Region of Denmark, the Danish Medicines Agency and the Danish Data Protection Agency. An external monitoring committee (The Good Clinical Practice Unit at Copenhagen University Hospitals) will oversee the trial. The results will be presented at international scientific meetings and through publications in peer-reviewed journals.Trial registration numbers2015-005163-16,NCT02905864, U1111-1171-4970Based on protocol versionV.6; 30 January 2017, 15:30 hours

scholarly journals Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults with Overweight or Obesity and Type 2 Diabetes Mellitus: A 54-Week Randomized Phase 2b Study

2021 ◽  
Author(s):  
Rajaa Nahra ◽  
Tao Wang ◽  
Kishore M. Gadde ◽  
Jan Oscarsson ◽  
Michael Stumvoll ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Weight Loss ◽  
Body Weight ◽  
Ad Hoc ◽  
Open Label ◽  
Double Blind ◽  
Glucagon Receptor ◽  
Nonalcoholic Fatty Liver ◽  
Design And Methods

<a><b>Objective: </b></a>Cotadutide, a <a>dual GLP-1 and glucagon receptor agonist</a>, is under development for nonalcoholic steatohepatitis (NASH) and type 2 diabetes. The effects of cotadutide on hepatic and metabolic parameters were evaluated in participants with overweight/obesity and type 2 diabetes. <p><b>Research Design and Methods:</b> In this phase 2b study, 834 adults with BMI ≥25kg/m<sup>2</sup> and type 2 diabetes inadequately controlled with metformin (glycated hemoglobin A1c [HbA1c] of 7.0%─10.5% [53─91 mmol/mol]) were randomized to double-blind cotadutide 100µg (n=100), 200µg (n=256), or 300µg (n=256), placebo (n=110), or open-label liraglutide 1.8mg (n=110), all administered subcutaneously (NCT03235050). Coprimary endpoints were changes in HbA1c and body weight at week 14.<b> </b>The originally randomized interventions were continued to week 54.<b> </b>Liver damage biomarkers and liver fibrosis algorithms were assessed.</p> <p><b>Results</b>: Cotadutide significantly decreased HbA1c and body weight at weeks 14 and 54 versus placebo (all <i>P</i><0.001). Improvements in lipid profile, aspartate aminotransferase and alanine aminotransferase levels, <a>PRO-C3 level, fibrosis-4 index</a>, and <a>nonalcoholic fatty liver disease fibrosis score</a> were observed with cotadutide 300µg versus placebo, but not with liraglutide. Weight loss with cotadutide 200µg was similar to liraglutide 1.8mg, and greater with cotadutide 300µg versus liraglutide 1.8mg. <a>The most common adverse events with cotadutide (nausea, 35%; vomiting, 17%) decreased over time. </a></p> <p><b>Conclusions: </b>Cotadutide treatment for 54 weeks improved glycemic control and weight loss in participants with overweight/obesity and type 2 diabetes. Ad hoc analyses demonstrated improvements in hepatic parameters and support further evaluation of cotadutide in NASH. </p>

COOPERATIVE MEASLES VACCINE FIELD TRIAL

PEDIATRICS ◽  
1966 ◽  
Vol 37 (4) ◽  
pp. 649-665
Author(s):  
Vincent F. Guinee ◽  
Donald A. Henderson ◽  
Helen L. Casey ◽  
Sara T. Wingo ◽  
Delmar W. Ruthig ◽  
...  
Keyword(s):  
Virus Vaccine ◽  
Field Trial ◽  
Hemagglutination Inhibition ◽  
Measles Virus ◽  
Live Vaccine ◽  
Measles Vaccine ◽  
Double Blind ◽  
Post Vaccination ◽  
Double Blind Placebo ◽  
Inhibition Antibody

The efficacy of two measles vaccine schedules was tested in a double-blind, placebo-controlled field trial. One group of children received three injections of 0.5 ml of inactivated measles virus vaccine. A second group received two injections of inactivated measles virus vaccine followed by 1400 TCID50 of live attenuated virus measles vaccine. Half of the participating children received placebo injections. The 4,758 participating children in kindergarten and first and second grades were kept under surveillance over a period of 14 months. Among these children 504 cases of clinically diagnosed measles occurred; 430 were in the placebo group. The inactivated measles virus vaccine, although providing good protection against cases of typical severity during the immediate 3 months after vaccination, showed a progressively decreasing level of efficacy over a year's period. At the end of a year, efficacy had fallen to 75%. The combined vaccine schedules demonstrated a consistently high order of protection, of about 95% or better, throughout the study period. The efficacy of two measles vaccine schedules—three injections of 0.5 ml of inactivated measles virus vaccine and two doses of inactivated virus vaccine followed by one dose of live vaccine—was tested in a double-blind, placebo-controlled study among 4,758 children in kindergarten and first and second grades. Measles hemagglutination inhibition antibody titers were measured on a randomly selected sample of study participants immediately before and 1, 8, and 14 months after the third injection. Although over 90% of those given the inactivated virus vaccine demonstrated detectable hemagglutination inhibition antibody 1 month post-vaccination, only 50% were seropositive 14 months later. Some clinically typical measles cases did occur among children in whom the inactivated virus vaccine had evoked an initial antibody response. Of those children receiving two doses of inactivated virus vaccine followed by live vaccine, 97% showed seroconversion 1 month post-vaccination. Fourteen months later 89% still had detectable antibody. Fourfold or greater titers occurred in some children in both vaccine groups without evident clinical measles illnesses. These titer "boosts" were considered to be on the basis of subclinical measles infections.

Sign in / Sign up

Export Citation Format

Share Document